Effect of ADMA levels on severity of erectile dysfunction in chronic kidney disease and other risk factors

Authors

  • Kaan Gökçen Assistant Professor; M.D. Cumhuriyet University, Department of Urology, Sivas,TURKEY
  • Hakan Kılıçarslan Professor; M.D. Uludağ University, Department of Urology, Bursa, Turkey
  • Burhan Coşkun Specialist; M.D., Uludağ University, Department of Urology, Bursa, Turkey
  • Alparslan Ersoy Professor; M.D., Uludağ University, Department of Nephrology, Bursa, Turkey
  • Onur Kaygısız Specialist; M.D., Uludağ University, Department of Urology, Bursa, Turkey
  • Yakup Kordan Associate Professor; M.D., Uludağ University, Department of Urology, Bursa, Turkey

DOI:

https://doi.org/10.5489/cuaj.3170

Abstract

Introduction: Hormonal, neurogenic, vasculogenic, and psychogenic impairments, as well as endothelial dysfunction may play a role in erectile dysfunction (ED) in patients with chronic kidney disease (CKD). Asymmetrical dimethylarginine (ADMA) is an inhibitor of nitric oxide, which is the key element of ED. ADMA levels are increased in CKD. We aimed to evaluate the effect of serum ADMA, prolactin, testosterone, and hemoglobin levels on erectile function of patients with CKD and control subjects.

Methods: A total of 42 men with CKD and 25 age-matched controls were enrolled. The patients with CKD were categorized into group 1 and group 2 based on whether they had ED according to their response to International Index of Erectile Function questionnaire (IIEF-EFD). Group 3 was a control group. Serum ADMA, total testosterone prolactin, and hemoglobin levels of the patients were evaluated.

Results: Serum ADMA, testosterone, and hemoglobin levels were similar between group 1 and 2, serum prolactin level was significantly high in group 1 than in group 2 or 3 (control group). There was no correlation between ADMA levels and IIEF-EFD scores of patients with CKD.

Conclusions: The results of this study suggest serum ADMA level is not related with ED in patients with CKD. Also, low testosterone and hemoglobin levels were not significant factors. High levels of serum prolactin are related with ED in patients with CKD.

Downloads

Download data is not yet available.

Downloads

Published

2016-01-14

How to Cite

Gökçen, K., Kılıçarslan, H., Coşkun, B., Ersoy, A., Kaygısız, O., & Kordan, Y. (2016). Effect of ADMA levels on severity of erectile dysfunction in chronic kidney disease and other risk factors. Canadian Urological Association Journal, 10(1-2), E41–5. https://doi.org/10.5489/cuaj.3170

Issue

Vol. 10 No. 1-2 (2016): CUAJ January

Section

Case Series

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.